La Synthèse on line : réflexions financières, économiques et sur la mondialisation

Langues

Par thème

Par secteur d'activité

Par pays

Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...

UCB [BE0003739530/UCB]

[09/02/2024]

UCB : UCB Media Room: Latest analyses of bimekizumab phase 3 studies in moderate to severe hidradenitis suppurativa to be presented at EHSF 2024

Lire le communiqué

UCB [BE0003739530/UCB]

[06/02/2024]

UCB : UCB Media Room: Transparency notification FMR LLC

Lire le communiqué

UCB [BE0003739530/UCB]

[08/01/2024]

UCB : UCB Media Room: European Commission approval of RYSTIGGO®▼ (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis in Europe

Lire le communiqué

UCB [BE0003739530/UCB]

[27/12/2023]

UCB : BIMZELX® (bimekizumab) Receives Approval in Japan for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Lire le communiqué

UCB [BE0003739530/UCB]

[04/12/2023]

UCB : UCB Media Room: European Commission approval of ZILBRYSQ®▼ (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis

Lire le communiqué

UCB [BE0003739530/UCB]

[23/11/2023]

UCB : UCB Media Room: Transparency notification Wellington

Lire le communiqué

UCB [BE0003739530/UCB]

[16/11/2023]

UCB : UCB Media Room: ‘Rheumacensus’ experts unite and call for essential psoriatic arthritis and axial spondyloarthritis care improvements

https://mb.cision.com/Public/18595/3877036/bbe6d7acff578d00_800x800ar.png =E2=80=98Rheumacensus=E2=80=99 experts unite and call for essential psor= iatic arthritis and axial spondyloarthritis care improvements =C2=B7 UCB is sponsoring an expertled, panEuropean multistakeholder progr= amme called Rheumacensus=C2=A0 =C2=B7 The programme brings together a variety of stakeholders to... Lire le communiqué

Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...

Vidéos

Gestionnaires,
Emetteurs,

Votre vidéo ici

Ma sélection

Les communiqués les plus lus de UCB